Hypofractionated stereotactic body radiotherapy in low- and intermediate-risk prostate carcinoma
Authors:
Open Access
- 31 December 2016
- journal article
- Published by Korean Society for Therapeutic Radiology and Oncology in Radiation Oncology Journal
- Vol. 34 (4) , 260-264
Abstract
Stereotactic body radiotherapy (SBRT) takes advantage of low α/β ratio of prostate cancer to deliver a large dose in few fractions. We examined clinical outcomes of SBRT using CyberKnife for the treatment of low- and intermediate-risk prostate cancer. This study was based on a retrospective analysis of the 33 patients treated with SBRT using CyberKnife for localized prostate cancer (27.3% in low-risk and 72.7% in intermediate-risk). Total dose of 36.25 Gy in 5 fractions of 7.25 Gy were administered. The acute and late toxicities were recorded using the Radiation Therapy Oncology Group scale. Prostate-specific antigen (PSA) response was monitored. Thirty-three patients with a median 51 months (range, 6 to 71 months) follow-up were analyzed. There was no biochemical failure. Median PSA nadir was 0.27 ng/mL at median 33 months and PSA bounce occurred in 30.3% (n = 10) of patients at median at median 10.5 months after SBRT. No grade 3 acute toxicity was noted. The 18.2% of the patients had acute grade 2 genitourinary (GU) toxicities and 21.2% had acute grade 2 gastrointestinal (GI) toxicities. After follow-up of 2 months, most complications had returned to baseline. There was no grade 3 late GU and GI toxicity. Our experience with SBRT using CyberKnife in low- and intermediate-risk prostate cancer demonstrates favorable efficacy and toxicity. Further studies with more patients and longer follow-up duration are required.Keywords
Funding Information
- Inha University
This publication has 22 references indexed in Scilit:
- Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2012Cancer Research and Treatment, 2015
- Prostate Cancer, Version 2.2014Journal of the National Comprehensive Cancer Network, 2014
- Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 yearsRadiation Oncology, 2013
- Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experienceRadiation Oncology, 2013
- Long-Term Outcomes From a Prospective Trial of Stereotactic Body Radiotherapy for Low-Risk Prostate CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Hypofractionated stereotactic body radiotherapy in low‐risk prostate adenocarcinomaCancer, 2011
- Acute and Late Toxicity in a Randomized Trial of Conventional Versus Hypofractionated Three-Dimensional Conformal Radiotherapy for Prostate CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomesRadiation Oncology, 2011
- What hypofractionated protocols should be tested for prostate cancer?International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2003
- Fractionation and protraction for radiotherapy of prostate carcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1999